On December 7, 2022 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, reported plans to present new clinical data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, and its hereditary cancer test, Empower, at the 2022 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas (Press release, Natera, DEC 7, 2022, View Source [SID1234624915]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Natera will present two posters from the LEADER and I-SPY 2 clinical trials in HR+, HER2- breast cancer highlighting Signatera’s ability to detect recurrence and facilitate treatment response monitoring. A third poster from a multi-center study of over 1,900 patients will describe how hereditary cancer screening with Empower at the time of imaging can help to identify patients who may benefit from cancer risk management.
"We are excited to share data from these studies, which provide important insights about the value of MRD testing and hereditary cancer screening across the continuum of care for patients with breast cancer," said Minetta Liu, M.D., chief medical officer of oncology at Natera.
Information on the poster presentations are as follows:
Dec. 8, 2022, 5:00 pm CST
Monitoring for response and recurrence in neoadjuvant-treated hormone receptor-positive HER2-negative breast cancer by personalized circulating-tumor DNA testing
Poster Presentation: P5-05-05 | Presenter: Magbanua MJM
Dec. 9, 2022, 7:00 am CST
Cell-free DNA (cfDNA) monitoring in a phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor ribociclib for localized ER+/HER2- breast cancer (LEADER)
Spotlight Poster Presentation: PD17-03 | Presenter: Medford AJ
Implementation and outcomes of population-based hereditary cancer testing across a diverse multi-location breast imaging center
Poster Presentation: P6-02-06 | Presenter: Miltenburg D